A compromise arrangement has been reached between the UK government and the Association of the British Pharmaceutical Industry to delay price cuts from the newly-negotiated Pharmaceutical Price Regulation Scheme by one month. The Department of Health, in a statement, said the deal "means that more patients will benefit from a wider range of innovative drug treatments at a fair price to the National Health Service." Its objective is to cut the NHS' annual drug bill of about L11.0 billion ($16.50 billion).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze